Scientists Prime the Immune System as a Powerful Cancer Weapon

June 2, 2014

A Forbes article on a T cell immunotherapy for women with cervical cancer presented at the American Society of Clinical Oncology meeting referenced the University of Pennsylvania licensing deal with Novartis for its T cell technology. This study from researchers at the National Cancer Institute and others focusing on melanoma presented this year at ASCO reinforce the notion that immunotherapy is not just for one or two diseases; it has the potential to be applied to many.

Forbes article